Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Spicer

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Science Immunology|September 15, 2023
Lung tumor-infiltrating T<sub>reg</sub> have divergent transcriptional profiles and function linked to checkpoint blockade responseArbor G Dykema, Jiajia Zhang, Laurene S Cheung, et al.
Translational Lung Cancer Research|October 17, 2022
International expert consensus on immunotherapy for early-stage non-small cell lung cancerWenhua Liang, Kaican Cai, Qingdong Cao, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Science Immunology|September 15, 2023
Lung tumor-infiltrating T<sub>reg</sub> have divergent transcriptional profiles and function linked to checkpoint blockade responseArbor G Dykema, Jiajia Zhang, Laurene S Cheung, et al.
Translational Lung Cancer Research|October 17, 2022
International expert consensus on immunotherapy for early-stage non-small cell lung cancerWenhua Liang, Kaican Cai, Qingdong Cao, et al.
Pageof 10